VIDEO: Vaccines boosted survival among STEMI heart attack patients with COVID-19

A late-breaking study at ACC.22 showed differences in COVID-positive heart attack patients between 2020 and 2021. #ACC22 #ACC2022

A late-breaking study at ACC.22 showed differences in COVID-positive heart attack patients between 2020 and 2021. Cath lab photo by Jose Arellano, COVID image from NIH

Santiago Garcia, MD, lead author of the study and director of the structural heart program at The Christ Hospital in Cincinnati, Ohio, presented new data from the North American COVID-19 STEMI (NACMI) registry at ACC.22. Severity of heart attacks were reduced in vaccinated patients, with zero deaths in vaccinated patients in 2021.

Researchers share first human data on new interventional shunt procedure for HFpEF

Researchers are using an intra-atrial shunt to lower pressures between the upper chambers of the heart to relieve symptoms in HFpEF heart failure patients. The novel Noya device uses an RF ablation to cut a hole into the septum and then enlarge it using a stent that can then be removed from the body after the procedure. 

Researchers are using an intra-atrial shunt to lower pressures between the upper chambers of the heart to relieve symptoms in HFpEF patients. The novel Noya device uses an RF ablation to cut a hole into the septum and then enlarge it using a stent that can then be removed from the body after the procedure.  Images courtesy of Sun et al. and Circulation: Heart Failure.

The first-in-man study, completed by a team of cardiologists in China, included 10 patients presenting with HFpEF. 

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

Steven Nissen, MD, of the Cleveland Clinic, explains an ACC.22 late-breaking trial that looked at if an mRNA drug could greatly reduce lipoprotein(a).

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

Photo Gallery: ACC 2022 in pictures

The mitral valve visualized by a a GE NuVision 4D intra-cardiac echo (ICE) catheter a life-like surgical rendering technology on the Vivid E95 cardiac ultrasound system. The catheter was co-developed with Biosense Webster to perform EP procedures. It also can be used in place of TEE in structural heart procedures to eliminate the need for an interventional echocardiography.  #ACC22

The mitral valve visualized by a GE NuVision 4D intra-cardiac echo (ICE) catheter a life-like surgical rendering technology on the Vivid E95 cardiac ultrasound system. The catheter was co-developed with Biosense Webster to perform EP procedures. It also can be used in place of TEE in structural heart procedures to eliminate the need for an interventional echocardiography. 

Click through a wide variety of snapshots from ACC.22 in Washington, D.C. 

Renal denervation linked to significant blood pressure reductions after 3 years

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.
The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall and ablate the nerves controlling vasodilation, so the artery can be propped in the fully open position.

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet.